Hpv Infection clinical trials

Explore recruiting hpv infection clinical trials.

Recruiting hpv infection studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hpv Infection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Randomized, placebo-controlled, double-blind study to evaluate 2LPAPI® efficacy on the clearance of genital HR-HPV infections (PAPION study)

Belgium, Romania

Therapeutic use (Phase IV) EU CTIS Study details

Human papillomavirus vaccine effectiveness study among men who have sex with men

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden

Sweden

Therapeutic use (Phase IV) EU CTIS Study details

Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy of pre-surgical HPV9-valente vaccination in women treated with loop electrosurgical excision (LEEP) for high-grade cervical intraepithelial neoplasia (CIN2+) up to cervical cancer initially invasive (FIGO IA1) - HOPE 9 STUDY

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Registry-Based Extension of Protocol V503-001 in Countries with Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine as Administered to 16- to 26- Year- Old Women.

Norway, Sweden, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared with a Standard 3-dose Regimen in 16- to 26-Year Old Women

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hpv Infection trials by city

Hpv Infection in Toronto Hpv Infection in Vancouver Hpv Infection in Montreal Hpv Infection in Calgary Hpv Infection in Edmonton Hpv Infection in Ottawa Hpv Infection in Winnipeg Hpv Infection in Quebec City Hpv Infection in Hamilton Hpv Infection in Kitchener Hpv Infection in London Hpv Infection in Halifax Hpv Infection in New York Hpv Infection in Los Angeles Hpv Infection in Chicago Hpv Infection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease